A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 589 participants.

Also called NCT01860729

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 589 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01860729
Other papers using this trial's data
  • A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol The American journal of cardiology, 2017-08-15 DOI, PubMed 28624096

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01860729. Randomized; double masking; primary purpose treatment. Start 2013-05-13 (actual); primary completion 2015-05-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)
Condition
Hypercholesterolemia
Intervention (Drug)
Anacetrapib
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01860729
Content hash
a77418cbf8b202aa3ae3cdba441682cff2892b92c981e13d7949ca5b78229f3c